Navigation Links
Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
Date:2/8/2010

Space Shuttle Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

(Vocus) February 8, 2010 -- Space Shuttle Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

“Conducting research in microgravity is so unique that we are able to learn things about these microbes that we could not learn on the ground,” said John Porter, Chief Executive Officer of Astrogenetix. “By observing genetic changes within the microbes, we are hoping to identify biomarkers that will lead to a successful vaccine or therapeutic.”

The Company’s payload on Flight STS-130 consists of methicillin-resistant Staphylococcus aureus (MRSA) microbes in search of a target for a vaccine or therapeutic. Research will build on information gained during experiments conducted on board previous shuttle missions performed over the past year. On STS-130, Astrogenetix will continue to interrogate specific genes within a group of genes that show promise for identifying a vaccine or therapeutic candidate, to further narrow the scope of virulence determinants.

“The launch of STS-130 allows us to add to our data on potential druggable targets in MRSA, and we appreciate the opportunity to work with NASA to conduct this important work,” added Dr. Jeanne Becker, Chief Science Officer for Astrogenetix.

Astrogenetix has worked closely with NASA in an effort to fully utilize the International Space Station, one of NASA’s primary priorities. The Company’s space-based research has been designated as National Lab Pathfinder Missions by NASA to demonstrate the use of the International Space Station as a research platform for commercial research and development.

“By utilizing the unique environment of microgravity, we believe we can shorten the time frame and reduce the cost of developing medicines,” said Thomas B. Pickens III, Astrogenetix’s Chairman of the Board. “The International Space Station National Lab provides an incredible platform to conduct breakthrough research.”

About Astrogenetix, Incorporated
A subsidiary of Astrotech Corporation (Nasdaq: ASTC), Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.

The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3580584.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
5. Signalife Continues to Procure Purchase Orders, Revenues
6. AQUISS Continues Expansion Into New Territory
7. Let there be light: new magnet design continues magnet labs tradition of innovation
8. Biotech Continues Upward Climb in October
9. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
10. Online Career Site for Life Science Professionals Continues Growth
11. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... Buffalo, New York (PRWEB) , ... February 11, ... ... and analytical instruments for more than 150 years, continues today to pursue the ... to its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... Inc. (NYSE: BIOA ), a leader in renewable ... Ltd., its partner in the Sarnia ... CDN$25 million in the joint venture for 10% of ...  Mitsui will also play a stronger role in the ... , providing dedicated resources alongside BioAmber,s commercial team. ...
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
Breaking Biology Technology:
(Date:2/9/2016)... AWRE ), a leading supplier of biometrics software and services, ... December 31, 2015.  --> --> ... an increase of 61% compared to $4.3 million in the same ... was $2.6 million compared to $0.2 million in the fourth quarter ... Higher revenue and operating income in the fourth quarter of this ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
Breaking Biology News(10 mins):